The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3′:5′-cyclic monophosphate in platelets
Open accessAbstract
1. The involvement of intracellular 3′:5′-cyclic AMP in the inhibition of platelet aggregation by prostaglandin E1, isoprenaline and adenosine has been examined by a radiochemical technique. Platelet-rich plasma was incubated with radioactive adenine to incorporate 14C radioactivity into platelet nucleotides. Pairs of identically treated samples were taken, one for the photometric measurement of platelet aggregation induced by ADP, the other for estimation of the radioactivity of 3′:5′-cyclic AMP. 2. Theophylline, papaverine, dipyridamole and 2,6-bis-(diethanolamino)-4-piperidinopyrimido[5,4d]pyrimidine (compound RA233) were found to inhibit 3′:5′-cyclic AMP phosphodiesterase from platelets. At concentrations of 3′:5′-cyclic AMP greater than 50μm the most active inhibitor was dipyridamole; at 3′:5′-cyclic AMP concentrations less than 19μm, papaverine and compound RA233 were more active than dipyridamole. 3. In the presence of compound RA233 (50μm), the effectiveness of prostaglandin E1 as an inhibitor of platelet aggregation was increased tenfold. Compound RA233 also increased the stimulation by prostaglandin E1 of the incorporation of radioactivity into 3′:5′-cyclic AMP. 4. Compound RA233 (50μm) increased the effectiveness of both adenosine and 2-chloroadenosine as inhibitors of aggregation by 70–100-fold, and in the presence of compound RA233 both adenosine and 2-chloroadenosine stimulated the incorporation of radioactivity into 3′:5′-cyclic AMP; the extent of the stimulation was proportional to the logarithm of the nucleoside concentration. 5. Compound RA233 (100–500μm) inhibited platelet aggregation by itself and caused small increases in the radioactivity of 3′:5′-cyclic AMP. Partial positive correlations were found between the radioactivity of 3′:5′-cyclic AMP in platelets measured at the time of addition of the aggregating agent (ADP) and the extent to which the aggregation was inhibited. 6. The results are interpreted as indicating that adenosine, 2-chloroadenosine, isoprenaline, prostaglandin E1 and drugs that inhibit platelet 3′:5′-cyclic AMP phosphodiesterase all inhibit aggregation by a common mechanism involving intracellular 3′:5′-cyclic AMP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal
BORN, G. V. R. (1962) · Nature · doi:10.1038/194927b0 · Cited by 4,294
SATTIN, A., & RALL, T. W. (1970) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)15197-3 · Cited by 892
Cyclic 3′,5′-Adenosine Monophosphate in Human Blood Platelets
Salzman, E. W., & Neri, L. L. (1969) · Nature · doi:10.1038/224609a0 · Cited by 136
Adenyl cyclase in human platelets: Activity and responsiveness
Zieve, P. D., & Greenough, W. B. (1969) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(69)90368-4 · Cited by 110
Born, G. V. R. (1964) · Nature · doi:10.1038/202095b0 · Cited by 99
β-Adrenergic receptors in human platelets
Abdulla, Y. H. (1969) · Journal of Atherosclerosis Research · doi:10.1016/s0368-1319(69)80052-9 · Cited by 66
Inhibition and Reversal of Platelet Aggregation by Methyl Xanthines
Ardlie, G. N., Glew, G., Schultz, B., & Schwartz, C. E. (1967) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1655076 · Cited by 62
Powerful New Aggregator of Blood Platelets—2-Chloroadenosine-5′-diphosphate
Maguire, M. H., & Michal, F. (1968) · Nature · doi:10.1038/217571a0 · Cited by 26
Cited by
An L-arginine/nitric oxide pathway present in human platelets regulates aggregation.
Radomski, M. W., Palmer, R. M., & Moncada, S. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.13.5193 · Cited by 1,208
Modulation of human platelet adenylate cyclase by prostacyclin (PGX)
Gorman, R. R., Bunting, S., & Miller, O. V. (1977) · Prostaglandins · doi:10.1016/0090-6980(77)90018-1 · Cited by 654
Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets
Tateson, J. E., Moncada, S., & Vane, J. R. (1977) · Prostaglandins · doi:10.1016/0090-6980(77)90019-3 · Cited by 600
Two distinct adenosine-sensitive sites on adenylate cyclase.
Londos, C., & Wolff, J. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5482 · Cited by 574
Oates, J. A., Wood, A. J. J., & FitzGerald, G. A. (1987) · New England Journal of Medicine · doi:10.1056/nejm198705143162005 · Cited by 408
Moncada, S., & Korbut, R. (1978) · The Lancet · doi:10.1016/s0140-6736(78)91269-2 · Cited by 386
Whittle, B. J. R., Moncada, S., & Vane, J. R. (1978) · Prostaglandins · doi:10.1016/0090-6980(78)90216-2 · Cited by 336
Anti‐platelet therapy: phosphodiesterase inhibitors
Gresele, P., Momi, S., & Falcinelli, E. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04034.x · Cited by 304
Arachidonic acid-induced human platelet aggregation and prostaglandin formation
Silver, M. J., Smith, J. B., Ingerman, C., & Kocsis, J. J. (1973) · Prostaglandins · doi:10.1016/0090-6980(73)90121-4 · Cited by 272
Self-citationWolberg, G., Zimmerman, T. P., Hiemstra, K., Winston, M., & Chu, L.-C. (1975) · Science · doi:10.1126/science.167434 · Cited by 266
Metadata
- Authors
- Mills, D. C. B., & Smith, J. B.
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 1971-01-01
- Volume
- 121
- Issue
- 2
- Pages
- 185-196
- ISSN
- 0306-3283 (ISSN-L)
- OpenAlex
- W32226917
- Cited by
- 423
- References
- 8
- FWCI
- 18.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.